XML 25 R14.htm IDEA: XBRL DOCUMENT

Collaboration Agreement - Related Party	9 Months Ended
Collaboration Agreement - Related Party	Sep. 30, 2021
Related Party Transactions [Abstract]
Collaboration Agreement - Related Party	Collaboration Agreement - Related Party In August 2017, the Company entered into a Collaboration Agreement with Takeda related to the development of certain ARC molecules, as amended in April 2018, October 2018 and March 2020 (the “Collaboration Agreement”). The Collaboration Agreement was mutually terminated pursuant to a termination agreement dated November 8, 2021 (the “Termination Agreement”). Under the terms of the Termination Agreement, the Company is not required to satisfy any remaining performance obligations, the Company will not make any payments to or receive any future milestone or royalty payments from Takeda, and all options to license and rights of first negotiation held by Takeda under the Collaboration Agreement were terminated. The termination of the Collaboration Agreement is a type II subsequent event and, therefore, had no impact on the Company's the financial statements as of September 30, 2021. The remaining deferred revenue will be recognized as revenue in the fourth quarter of 2021. The Company received cash of $3.6 million and $12.1 million for the nine months ended September 30, 2021 and 2020, respectively, from Takeda and has recognized total aggregate revenue of $51.9 million through September 30, 2021 under the Collaboration Agreement. The Company recognizes revenue for the allocated up-front payments using a cost-based input measure. In applying the cost-based input method of revenue recognition, the Company used actual costs incurred relative to budgeted costs expected to be incurred for the combined performance obligation. In the second quarter of 2021, in connection with the Company’s modifications to the SL-279252 clinical development plan and its intention to expand the dose-escalation portion of its ongoing Phase 1 clinical trial, the estimated total costs related to the SL-279252 development program increased. The increase in expected total cost of the development program required to satisfy a specific performance obligation in the Collaboration Agreement, or the denominator in the cost-based input method, resulted in a cumulative-effect adjustment under ASC 250, Change in Accounting Estimates. Actual consideration received and total revenue expected to be recognized in accordance with the development of SL-279252 under the Collaboration Agreement remain unchanged. The Company recognizes revenue related to the reimbursable cost as they are incurred. The effects of this change in the Company’s estimates were a $4.2 million increase in 2021 net loss and a $0.10 increase in 2021 basic and diluted loss per share.